Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
- Collect , catalogue, and store biological specimens from patients with locally advanced
or metastatic breast cancer
- To collect clinical data from these patients containing identifiers, demographics,
epidemiologic review, clinical evaluation, treatment, and long-term follow-up.
- To provide an efficient bi-directional flow of clinical information and specimens
between laboratory and clinical scientists in order to foster innovative translational
OUTLINE: This is a multicenter study.
Patients undergo core biopsy and blood sampling at diagnosis, between chemotherapy regimens,
and prior to definitive surgery. Tumor markers are assessed using immunohistochemistry and
PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.
Observational Model: Case-Only, Time Perspective: Prospective
Generation of a biorepository for current and future correlative research studies
Diagnosis, between treatments,7-14 days after start of treatment and at time of definitive therapy
Lisa A. Carey, MD
UNC Lineberger Comprehensive Cancer Center
United States: Institutional Review Board
|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill||Chapel Hill, North Carolina 27599-7570|
|Nash Heathcare||Rocky Mount, North Carolina 27804|